PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

Platelet-derived growth factor receptor has been implicated in many malignant and non-malignant diseases. Platelet-derived growth factor receptor-α is a tyrosine kinase and a side target for imatinib, a revolutionary drug for the treatment of chronic myeloid leukemia that has dramatically improved t...

Full description

Bibliographic Details
Main Authors:	Sameer Ahmad Guru, Rashid Mir, Musadiq Bhat, Imtiyaz Najar, Mariyam Zuberi, Mamta Sumi, Mirza Masroor, Naresh Gupta, Alpana Saxena
Format:	Article
Language:	English
Published:	IOS Press 2017-10-01
Series:	Tumor Biology
Online Access:	https://doi.org/10.1177/1010428317713857

Similar Items

Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-α and PDGFR-β
by: Lingli Zhou, et al.
Published: (2018-07-01)

Imatinib in PDGFR positive malignant solitary fibrous tumour of the pleura
by: Sarah Bigeni, et al.
Published: (2016-03-01)

miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia
by: Anupama Ninawe, et al.
Published: (2021-03-01)

Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients
by: Rashid Mir, et al.
Published: (2016-01-01)

PDGFR-β mediated growth failure in pediatric CML cases on Imatinib
by: Prakamya Gupta, et al.
Published: (2020-09-01)

Imatinib atenua a fibrose miocárdica em associação com a inibição da atividade do PDGFRα Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity
by: Li-kun Ma, et al.
Published: (2012-12-01)

Imatinib atenua a fibrose miocárdica em associação com a inibição da atividade do PDGFRα Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity
by: Li-kun Ma, et al.
Published: (2012-01-01)

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer
by: Elizabeth Mack, et al.
Published: (2011-05-01)

Potential Impact of COMT-rs4680 G > A Gene Polymorphism in Coronary Artery Disease
by: Rashid Mir, et al.
Published: (2018-07-01)

Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
by: Mariyam Zuberi, et al.
Published: (2016-01-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Imatinib atenua a fibrose miocárdica em associação com a inibição da atividade do PDGFRα
by: Li-kun Ma, et al.
Published: (2012-12-01)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
by: Darlize Hübner Martins, et al.
Published: (2011-01-01)

Targeted treatment of chronic myeloid leukemia: role of imatinib
by: Ila Tamascar, et al.
Published: (2009-03-01)

Molecular mechanisms of imatinib resistance in chronic myeloid leukaemia
by: Wang, Lihui
Published: (2011)

Predictors of imatinib response in patients with chronic myeloid leukaemia
by: Crossman, Lucy C.
Published: (2006)

Bisphosphonates in the treatment of Imatinib-resistant chronic myeloid leukaemia
by: Chuah, Charles Thuan Heng
Published: (2006)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)

Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells.
by: Erxi Wu, et al.
Published: (2008-01-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Determination of drug sensitivity subgroups in acute myeloid leukemia to increase treatment efficacy by imatinib and its analog imatinib B
by: Can Turk, et al.
Published: (2021-09-01)

Evolution of treatment response to IMATINIB in patients diagnosed with chronic myeloid leukaemia
by: Mendes, Alexandrina Maria da Silva
Published: (2011)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
by: Aamer Aleem
Published: (2009-04-01)

Melasma-like pigmentation during imatinib therapy for chronic myeloid leukemia
by: Suyash Singh Tomar, et al.
Published: (2020-01-01)

Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
by: Chen X, et al.
Published: (2020-06-01)

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
by: Zheng Hu, et al.
Published: (2009-01-01)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
by: Waclaw J, et al.
Published: (2015-09-01)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
by: Charles Chuah, et al.
Published: (2009-04-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
by: Roberta Bitencourt, et al.
Published: (2011-12-01)